|
|
|
|
LEADER |
00000cam a2200000Mi 4500 |
001 |
EBOOKCENTRAL_ocn953863220 |
003 |
OCoLC |
005 |
20240329122006.0 |
006 |
m o d |
007 |
cr ||||||||||| |
008 |
160212s2013 enk o 000 0 eng d |
040 |
|
|
|a NLE
|b eng
|e rda
|e pn
|c NLE
|d EBLCP
|d MERUC
|d ZCU
|d ICG
|d USU
|d OCLCO
|d OCLCQ
|d OCLCO
|d VT2
|d AU@
|d OCLCO
|d OCLCF
|d OCLCQ
|d WYU
|d OCLCO
|d OCLCA
|d TKN
|d DKC
|d OCLCO
|d OCLCQ
|d OCLCA
|d YDX
|d TEF
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
019 |
|
|
|a 1006298867
|
020 |
|
|
|a 9781780843308
|q (Electronic book)
|
020 |
|
|
|a 1780843305
|
020 |
|
|
|a 1780843313
|q (electronic bk.)
|
020 |
|
|
|a 9781780843315
|q (electronic bk.)
|
020 |
|
|
|z 9781780843322
|
020 |
|
|
|z 1780843321
|
035 |
|
|
|a (OCoLC)953863220
|z (OCoLC)1006298867
|
037 |
|
|
|a 10.2217/9781780843308
|b Future Science
|
050 |
|
4 |
|a RC632.L5
|b .A383 2014
|
060 |
|
4 |
|a WD 200.5.H8
|
082 |
0 |
4 |
|a 616.3997
|2 23
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Advances in dyslipidemia /
|c editor Wilbert S. Aronow.
|
264 |
|
1 |
|a London :
|b Future Medicine Ltd,
|c 2013, ©2013.
|
300 |
|
|
|a 1 online resource (125 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
505 |
0 |
|
|a Advances in dyslipidemia -- Atherosclerosis: dyslipidemia, inflammation and lipoapoptosis -- Familial hypercholesterolemia: bridging and minding the gap in healthcare -- PCSK9 inhibition: drug development for low-density lipoprotein lowering -- Novel therapies for dyslipidemia -- The highs and lows of high-density lipoportein -- Do we need to treat patients with heart failure with statins? -- Management of dyslipidemia in patients with nonalcoholic fatty liver disease -- Dyslipidemia: current management and the challenge of residual cardiovascular risk reduction.
|
520 |
|
|
|a In eight expertly authored chapters, Advances in Dyslipidemia provides an excellent overview for any physician taking care of patients with atherosclerotic vascular disease or at high-risk or moderate-risk for atherosclerotic vascular disease.
|
590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
650 |
|
0 |
|a Lipids
|x Metabolism
|x Disorders.
|
650 |
|
0 |
|a Blood cholesterol.
|
650 |
|
0 |
|a Blood lipids.
|
650 |
|
2 |
|a Dyslipidemias
|
650 |
|
6 |
|a Cholestérolémie.
|
650 |
|
6 |
|a Lipides plasmatiques.
|
650 |
|
7 |
|a Blood cholesterol
|2 fast
|
650 |
|
7 |
|a Blood lipids
|2 fast
|
650 |
|
7 |
|a Lipids
|x Metabolism
|x Disorders
|2 fast
|
700 |
1 |
|
|a Aronow, Wilbert S.,
|e editor.
|
758 |
|
|
|i has work:
|a Advances in dyslipidemia (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFtftRHVrXQQJkp7vQvtBq
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=5092476
|z Texto completo
|
938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL5092476
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 14880238
|
994 |
|
|
|a 92
|b IZTAP
|